Condition: Diphtheria-Tetanus-acellular Pertussis Vaccines · Sponsor: GlaxoSmithKline
The purpose of this Phase 3, non-randomized, single-arm, open-label study is to evaluate the immune response, reactogenicity and safety of GSKs dTpa vaccine in Japanese pregnant women between 27 weeks and less than 37 weeks of pregnancy. Both the pregnant women and their neonates born during the study will be evaluated for specific analyses.
This description comes directly from the study's public registry record.
US GSK Clinical Trials Call Center · 877-379-3718 · GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Center · +44 (0) 20 89904466 · GSKClinicalSupportHD@gsk.com
Always discuss trial participation with your own doctor first.
| GSK Investigational Site | Chiba, Japan | Recruiting |
| GSK Investigational Site | Chiba, Japan | Recruiting |
| GSK Investigational Site | Fukui, Japan | Recruiting |
| GSK Investigational Site | Fukuoka, Japan | Recruiting |
| GSK Investigational Site | Fukushima, Japan | Recruiting |
| GSK Investigational Site | Hokkaido, Japan | Recruiting |
| GSK Investigational Site | Kanagawa, Japan | Recruiting |
| GSK Investigational Site | Kyoto, Japan | Recruiting |
| GSK Investigational Site | Nagano, Japan | Recruiting |
| GSK Investigational Site | Osaka, Japan | Recruiting |
| GSK Investigational Site | Osaka, Japan | Recruiting |
| GSK Investigational Site | Saitama, Japan | Recruiting |
+ 6 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07596199